Table 1.

The effects of FrdMO and DprMO on head formation and morphogenesis

Phenotypes (%)
Morphogenetic defects with
Experimental groupsDose/embryon*NormalNormal headMicrocephalyAcephaly
Control MO 16 ng 70 90 
FrdMO 16 ng 38 26 61 
DprMO 8 ng 40 15 32 50 
FrdMO+DprMO 4 ng+2 ng 55 29 18 29 24 
FrdMO+DprMO+Frodo 4 ng+2 ng+1 ng 56 59 20 16 
FrdMO+DprMO 8 ng+4 ng 97 10 25 63 
FrdMO+DprMO+Frodo 8 ng+4 ng+1 ng 65 22 35 38 
FrdMO+DprMO+βcat 8 ng+4 ng+10 pg 61 67 (18) 23 
Phenotypes (%)
Morphogenetic defects with
Experimental groupsDose/embryon*NormalNormal headMicrocephalyAcephaly
Control MO 16 ng 70 90 
FrdMO 16 ng 38 26 61 
DprMO 8 ng 40 15 32 50 
FrdMO+DprMO 4 ng+2 ng 55 29 18 29 24 
FrdMO+DprMO+Frodo 4 ng+2 ng+1 ng 56 59 20 16 
FrdMO+DprMO 8 ng+4 ng 97 10 25 63 
FrdMO+DprMO+Frodo 8 ng+4 ng+1 ng 65 22 35 38 
FrdMO+DprMO+βcat 8 ng+4 ng+10 pg 61 67 (18) 23 

Morpholinos (MOs) and mRNAs as indicated above were injected into the equatorial region of two dorsal blastomeres at four-cell stage. Morphological defects were scored at stages 33-35 and expressed as percentage of total number of injected embryos.

Incomplete blastomeres closure (n=44, 98%) was observed in embryos injected with FrdMO and DprMO (8 ng+4 ng), and to a lesser degree in embryos injected with FrdMO (16 ng) or DprMO (8 ng) separately (n=40, 20% and n=38, 32%, respectively).

Data were obtained from three separate experiments.

*

n, number of scored embryos

Percentage of embryos with enlarged head

Close Modal

or Create an Account

Close Modal
Close Modal